Nuzenio

Line Lurbinectedin

Line Lurbinectedin news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 4 latest news signals 4 publisher sources 100/100 entity strength

Latest news

Jazz Seeks FDA Withdrawal of Second-Line Lurbinectedin SCLC Indication - MedscapeMedscape · Fri, 07 Aug 2026 08:24:31 GMTLurbinectedin Second-Line SCLC Indication to Be Withdrawn After LAGOON - Targeted OncologyTargeted Oncology · Wed, 05 Aug 2026 14:09:27 GMTWithdrawal Planned for Second-Line Lurbinectedin in SCLC Indication - CancerNetworkCancerNetwork · Wed, 05 Aug 2026 14:09:23 GMTJazz to withdraw Zepzelca with FDA in second-line small cell lung cancer - Fierce PharmaFierce Pharma · Tue, 04 Aug 2026 13:18:16 GMT

Timeline

Fri, 07 Aug 2026 08:24:31 GMTJazz Seeks FDA Withdrawal of Second-Line Lurbinectedin SCLC Indication - Medscape
Wed, 05 Aug 2026 14:09:27 GMTLurbinectedin Second-Line SCLC Indication to Be Withdrawn After LAGOON - Targeted Oncology
Wed, 05 Aug 2026 14:09:23 GMTWithdrawal Planned for Second-Line Lurbinectedin in SCLC Indication - CancerNetwork
Tue, 04 Aug 2026 13:18:16 GMTJazz to withdraw Zepzelca with FDA in second-line small cell lung cancer - Fierce Pharma

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Line Lurbinectedin.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

4 distinct publisher/source names are currently connected to this entity page.